Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1Phase 2/3 1

Status

Recruiting 2Completed 2Terminated 1

Sponsor Class

OTHER 5

Study Type

Interventional 5Observational 2

Sponsor

Cancer Type

Gastrointestinal 5Endocrine 5NET 4Genitourinary 1

Conditions

Neuroendocrine Tumors 4Gastro-enteropancreatic neuroendocrine tumor 1Carcinoid Tumor 1

Interventions

Everolimus 59lutetium Lu 177 dotatate 46Magnetic Resonance Spectroscopy 33pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 24lanreotide 23cabozantinib 22pasireotide 21gallium Ga 68 dotatate 21lenvatinib 20Etoposide 19Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18Sunitinib 17Bevacizumab 16trametinib 15dabrafenib 15Doxorubicin 143-Iodobenzylguanidine 14surufatinib 13Sorafenib 13Ipilimumab 13Thyrotropin Alfa 12Injections 12Positron Emission Tomography Computed Tomography 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Somatostatin × Endocrine × Clear all
NCT06855095 2025-03-03

ATSA

The Netherlands Cancer Institute

Phase 2/3 Recruiting
39 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT02795858 2025-02-19

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

Dana-Farber Cancer Institute

Phase 2 Completed
43 enrolled 11 charts
Endocrine

Carcinoid Tumor

NCT05701241 2024-06-14

SAUNA

University Hospital, Antwerp

Phase 4 Recruiting
270 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT04129255 2020-09-10

CSMS99

National Cancer Institute, Naples

Phase 2 Completed
34 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT01755182 2016-05-06

LOTUS

National Cancer Institute, Naples

Phase 3 Terminated
1 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡